Globus Medical price target lowered to $58 from $63 at Wells Fargo

Wells Fargo lowered the firm’s price target on Globus Medical to $58 from $63 and keeps an Equal Weight rating on the shares. The updated price target includes the NuVasive acquisition, and the company continues to expect $170M in cost synergies by the third year, the analyst tells investors in a research note.